You just read:

Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance

News provided by

Oxford BioTherapeutics

Dec 09, 2013, 07:11 ET